Energy & Endurance
SLU-PP-332
← Back to Library
Limited / unverified Limited / unverified Limited / unverified Metabolic Mitochondrial
Educational reference only. Read the full disclaimer.
The protocols below are not automatically an FDA-approved or clinically verified regimen unless
explicitly marked as label-verified or clinical-trial above.
Overview
Route(s): Subcutaneous, Oral
Typical vial sizes: 10, 30 mg
Dosing window: Morning / Pre-Workout
Receptor / target: ERR Agonist
Properties: Not stated
Pre-mixed: No
Unverified protocol notes
Standard Protocol
| Timeframe | Dose | Notes |
|---|---|---|
| Weeks 1-8 | 1.0mg to 2.0mg daily | Administered in the morning or pre-workout. |
Unverified protocol note; not label dosing unless graded otherwise on this page.
Alternative Titration 1 - 60mg Week Max Oral Tabs
| Timeframe | Dose | Notes |
|---|---|---|
| Week 1 | 20mg am pre-workout or 7am | |
| Week 2 | 20mg am pre-workout, 20mg 11am | |
| Weeks 3-8 | 40mg am pre-workout, 20mg 11am, 20mg 2pm |
Unverified alternative protocol; not an approved-label regimen unless graded otherwise on this page.
Alternative Titration 2 - 80mg Week Max Oral Tabs
| Timeframe | Dose | Notes |
|---|---|---|
| Week 1 | 20mg am pre-workout or 7am | |
| Week 2 | 20mg am pre-workout, 20mg 11am | |
| Weeks 3 | 40mg am pre-workout, 20mg 11am | |
| Weeks 4-8 | 40mg am pre-workout, 20mg 11am, 20mg 2pm |
Unverified alternative protocol; not an approved-label regimen unless graded otherwise on this page.
Alternative Titration 3 - 100mg week Max Oral Tabs
| Timeframe | Dose | Notes |
|---|---|---|
| Week 1 | 20mg am pre-workout or 7am | |
| Week 2 | 20mg am pre-workout, 20mg 11am | |
| Weeks 3 | 40mg am pre-workout, 20mg 11am | |
| Weeks 4-5 | 40mg am pre-workout, 20mg 11am, 20mg 2pm | |
| Weeks 6-8 | 60mg am pre-workout, 20mg 11am, 20mg 2pm |
Unverified alternative protocol; not an approved-label regimen unless graded otherwise on this page.
Protocol logic check
Protocol context: Energy protocols are usually about mitochondrial or metabolic signaling. The logic is timing around meals/training, avoiding late-day stimulation, and watching sleep, glucose, blood pressure, and overtraining signals. Entry context: target (ERR Agonist); route Subcutaneous/Oral; timing Morning / Pre-Workout. Limited-evidence dosing tables are hypotheses, not recommendations.
Independent evidence
Independent safety notes: No independent approved-label regimen is listed for this entry. Dosing notes remain unverified.
Regulatory status: no approved label identified
Storage
No independently verified storage guidance found. Treat any unverified storage claim as unverified, and see the general storage guidance in the FAQ.
Contraindications (limited evidence)
- Active malignancy: ERRα is overexpressed in multiple cancers including breast, ovarian, and prostate cancer where it promotes tumor survival, metastasis, and OXPHOS upregulation that supports tumor bioenergetics; SLU-PP-332's ERR agonism could activate these same pro-tumor transcriptional programs. Limited / unverified
- Hormone-sensitive cancers (breast, ovarian, prostate, endometrial): while ERRs are mechanistically distinct from estrogen receptors, they share pathway convergence in hormone-sensitive tissues and have documented roles in driving progression of these cancers. Limited / unverified
- Pregnancy: ERR nuclear receptors are involved in trophoblast development and placental energy metabolism; exogenous ERR agonism during pregnancy is not established as safe. Limited / unverified
- Breastfeeding: no safety data established. Limited / unverified
- Known hypersensitivity to SLU-PP-332 or related quinazolinone compounds. Limited / unverified
- Severe cardiac arrhythmia or decompensated heart failure: ERRα is highly expressed in cardiac tissue and drives the cardiac OXPHOS gene program; in decompensated heart failure where cardiac energy metabolism is already dysregulated, supraphysiological ERR agonism may produce uncharacterized and potentially adverse effects. Limited / unverified
- Pediatric use: ERR receptors are involved in developmental biology; safety in children is not established. Limited / unverified
- Concurrent use with other PGC-1α or ERR-modulating agents: the magnitude of overlapping mitochondrial biogenesis stimulation from multiple simultaneous pathway activators is not characterized. Limited / unverified
Side effects (limited evidence)
- Mild lethargy post-dose during initiation: the metabolic reprogramming demands cellular resources during the gene expression transition phase; most pronounced in weeks 1-2 as new mitochondrial proteins are being synthesized; resolves as the oxidative capacity becomes established. Limited / unverified
- Injection site irritation: redness, soreness, minor swelling at subcutaneous administration site; standard response. Limited / unverified
- Insomnia or sleep disruption: ERR agonism and mitochondrial biogenesis drive upregulated metabolic rate; dosing in the afternoon or evening may produce difficulty falling asleep; morning and pre-workout dosing protocols exist specifically to prevent this. Limited / unverified
- GI discomfort with oral tablet formulations: nausea, abdominal bloating, or loose stools at higher oral doses; the split oral dosing schedules (morning, 11am, 2pm) distribute the load to reduce peak GI exposure. Limited / unverified
- Potential cardiovascular effects: ERRα's cardiac expression means SLU-PP-332 has cardiac metabolic activity; in healthy subjects this is likely beneficial but cardiac effects in diseased tissue are not characterized. Limited / unverified
- Theoretical ERR-mediated cancer cell activation: the most significant theoretical adverse concern; the same transcriptional programs SLU-PP-332 activates for metabolic benefit in healthy tissue overlap with pro-tumor ERRα programs in oncological contexts. Limited / unverified
- Unknown long-term adverse effects: no published Phase 1 human clinical trial data exists as of mid-2026; the complete human adverse event profile is genuinely uncharacterized beyond animal studies and early research observation. Limited / unverified
- No estrogenic side effects: despite the "estrogen-related" nomenclature, SLU-PP-332 does not activate ERα or ERβ estrogen receptors and produces no estrogenic effects (gynecomastia, feminization, HPTA suppression). Limited / unverified
Compatibility
The relationships below come from the source site's internal engine and were not verified independently. Treat them as a starting point for a conversation with a clinician. They carry no safety guarantee.
Reported synergistic:
Reported contraindicated combinations:
None listed.